secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0000914475-23-000013
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Biosciences adopts proxy access bylaw and updates stockholder nomination procedures
--------------------------------------------------------------------------------

- Proxy access: stockholder(s) holding 3%+ for 3+ years can nominate up to 2 or 20% of directors.
- Updated procedural requirements for nominations and proposals, including Rule 14a-19 compliance.
- Nominees must provide updated disclosures as of the record date and 5 business days before the meeting.
- Nominations disregarded if stockholder fails to comply with Rule 14a-19 or provide timely evidence.
- Consent actions require notice to fix record date and use of independent inspectors to validate consents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000013/0000914475-23-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000013/nbix-20230210.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer